Eptifibatide txhaj tshuajyog ib qho tshuaj antiplatelet feem ntau siv rau thromboprophylaxis hauv mob plawv mob plawv (ACS) thiab percutaneous coronary intervention (PCI). Nws yog cov kua uas tsis muaj xim los yog yuav luag tsis muaj xim, feem ntau yog muab tso rau hauv cov hlab ntsha. Nws cov nyhuv yog nrawm thiab thim rov qab, thiab nws tuaj yeem cuam tshuam cov platelet ua haujlwm tsis pub dhau 1 teev tom qab txhaj tshuaj. Cov nyhuv tuaj yeem kav ntev li 2-4 teev, thiab platelet ua haujlwm maj mam rov qab los tom qab txiav cov tshuaj. Cov yam ntxwv no ua rau nws muaj txiaj ntsig tshwj xeeb hauv cov xwm txheej kho mob uas yuav tsum tau ua kom ceev cov tshuaj antiplatelet thiab tej zaum yuav muaj kev pheej hmoo los ntshav.
Peb cov khoom Description
Eptifibatide COA
 |
||
| Certificate of Analysis | ||
| Compound npe | Eptifibatide | |
| Qib | Pharmaceutical qib | |
| CAS Nr. | 188627-80-7 | |
| Ntau | 70g | |
| Ntim txheem | PE hnab + Al foil hnab | |
| Chaw tsim tshuaj paus | Shaanxi BLOOM TECH Co., Ltd | |
| Ntau No. | 202601090078 | |
| MFG | Peb 9, 2026 | |
| EXP | Peb 8, 2029 | |
| Qauv |
|
|
| Yam khoom | Enterprise txheem | Kev txheeb xyuas qhov tshwm sim |
| Qhov tshwm sim | Dawb los yog yuav luag dawb hmoov | Ua raws |
| Cov ntsiab lus dej | Tsawg dua lossis sib npaug li 5.0% | 0.54% |
| Poob rau ziab | Tsawg dua lossis sib npaug li 1.0% | 0.42% |
| Hnyav Hlau | Pb Tsawg dua lossis sib npaug li 0.5ppm | N.D. |
| Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Hg Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Cd Tsawg dua lossis sib npaug li 0.5ppm | N.D. | |
| Purity (HPLC) | Ntau dua lossis sib npaug li 99.0% | 99.98% |
| Ib leeg impurity | <0.8% | 0.52% |
| Tag nrho microbial suav | Tsawg dua lossis sib npaug li 750cfu / g | 95 |
| E. Coli | Tsawg dua lossis sib npaug li 2MPN / g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (los ntawm GC) | Tsawg dua lossis sib npaug li 5000ppm | 500ppm ua |
| Cia |
Khaws rau hauv qhov chaw kaw, tsaus, thiab qhuav hauv qab -20 degree |
|
|
|
||
|
|
||
| Tshuaj Formula | C35H49N11O9S2 |
| Exact Mass | 831 |
| Molecular Luj | 832 |
| m/z | 831 (100.0%), 832 (37.9%), 833 (9.0%), 833 (7.0%), 832 (4.1%), 834 (3.4%), 833 (1.8%), 832 (1.6%), 833 (1.1%) |
| Elemental Analysis | 831 (100.0%), 832 (37.9%), 833 (9.0%), 833 (7.0%), 832 (4.1%), 834 (3.4%), 833 (1.8%), 832 (1.6%), 833 (1.1%) |
Eptifibatide txhaj tshuajRaws li ib qho tshwj xeeb platelet glycoprotein IIb / IIIa receptor antagonist, plays lub luag haujlwm tseem ceeb hauv kev kho cov kab mob plawv los ntawm kev inhibiting platelet aggregation. Cov nram qab no muaj xws li: kev kho mob ntawm tus mob coronary syndrome, kev pab ntawm percutaneous coronary intervention, tiv thaiv kab mob thrombotic, txhim kho vascular muaj nuj nqi, ncua ntawm atherosclerosis kev vam meej, thiab kev tswj ntawm inflammatory tshuaj.
Kev kho mob ntawm tus mob coronary syndrome
Acute coronary syndrome (ACS) encompasses unstable angina thiab non ST ntu elevation myocardial infarction, nrog nws cov txheej txheem pathological yog tsim ntawm thrombus hauv cov hlab ntsha, ua rau myocardial ischemia. Los ntawm tshwj xeeb thaiv cov glycoprotein IIb / IIIa receptor nyob rau saum npoo ntawm platelets, kev khi ntawm fibrinogen rau cov receptor no tau zoo inhibited. Cov txheej txheem kev khi no yog txoj hauv kev tseem ceeb rau platelet cross-txuas thiab sib sau ua ke, thiab kev cuam tshuam ntawm eptipatide zoo li txiav tawm qhov txuas tseem ceeb ntawm txoj kev no, yog li sai thiab zoo inhibiting platelet activation thiab aggregation, txo qhov kev pheej hmoo ntawm thrombosis, thiab thim rov qab cov ntshav tsis txaus los ntawm thrombosis.
Cov kev tshawb fawb soj ntsuam tau muab cov ntaub ntawv pov thawj zoo rau kev kho mob hauv cov mob coronary syndrome. Hauv cov neeg mob uas tsis ruaj khov angina thiab tsis yog ST ntu nce myocardial infarction, kev siv cov tshuaj no ua ke nrog kev kho mob aspirin thiab heparin tuaj yeem txo qhov tshwm sim ntawm cov xwm txheej kawg xws li kev tuag, myocardial infarction, lossis kev kho mob xwm txheej ceev hauv 30 hnub. Qhov kev sib xyaw ua ke kev kho mob no tau siv tag nrho cov txiaj ntsig kev sib koom ua ke ntawm ntau yam tshuaj, nrog kev cuam tshuam los ntawm platelet aggregation qib los ntawm eptipatide, inhibition ntawm platelet cyclooxygenase los ntawm cov tshuaj aspirin kom txo qis kev tsim cov thromboxane A2, thiab cov nyhuv anticoagulant los ntawm heparin. Qhov sib xyaw ua ke ntawm peb qhov muab cov neeg mob nrog kev tiv thaiv ntau dua.
Nws cov nyhuv inhibitory muaj qhov txawv txav. Tom qab txiav tawm, platelet muaj nuj nqi tuaj yeem maj mam rov qab los, uas ua rau nws muaj txiaj ntsig zoo nyob rau hauv cov xwm txheej kho mob uas yuav tsum tau ceev cov tshuaj antiplatelet thiab tej zaum yuav muaj kev pheej hmoo los ntshav. Piv txwv li, nyob rau hauv cov neeg mob uas muaj mob coronary syndrome, lub siab tshaj plaws ntshav tshuaj concentration yuav mus txog 5 feeb tom qab txhaj tshuaj intravenously, inhibiting platelet muaj nuj nqi nyob rau hauv 1 teev, thiab cov nyhuv yuav kav ntev li 2-4 teev. Qhov pib sai sai no thiab lub sijhawm luv luv ntawm kev ua haujlwm pub rau cov kws kho mob kho cov phiaj xwm kho mob raws sijhawm raws li kev hloov pauv ntawm tus neeg mob tus mob, tswj tau zoo thrombosis thaum txo qhov kev pheej hmoo los ntshav mus ntev.
Qhov chaw:39Drug Tong, Minfukang, Baidu Baike
Pab percutaneous coronary intervention therapy
Percutaneous coronary intervention (PCI) yog ib qho kev kho mob tseem ceeb rau kab mob plawv. Txawm li cas los xij, catheter manipulation thaum lub sij hawm phais yuav ua rau cov vascular endothelium ua kom cov platelets thiab coagulation systems, thiab ua rau muaj teeb meem loj xws li stent thrombosis. Ua si ntau lub luag haujlwm tseem ceeb thaum lub sijhawm ua haujlwm ntawm PCI:
Tiv thaiv kev tsim stent thrombosis
Los ntawm tsis tu ncua inhibiting platelet aggregation, qhov kev pheej hmoo ntawm stent nto thrombus txuas tuaj yeem txo qis. Cov kev tshawb fawb soj ntsuam tau pom tias kev tso dej tsis tu ncua ntawm etibacide tom qab PCI tuaj yeem txo qhov tshwm sim ntawm stent thrombosis, tshwj xeeb tshaj yog rau cov neeg mob uas muaj kab mob nyuaj lossis muaj kev pheej hmoo siab (xws li ntshav qab zib, kab mob ntau lub nkoj). Cov neeg mob no muaj kev pheej hmoo siab dua los ntawm kev tsim cov stent thrombosis vim qhov mob vascular tsis zoo lossis ntau yam kab mob hauv qab, thiab kev siv eptifibatide muab rau lawv nrog kev lees paub kev nyab xeeb dua.
Txo qhov kev pheej hmoo ntawm cov kab mob thrombotic lig
Post PCI cov neeg mob muaj kev pheej hmoo ntawm theem kawg ntawm thrombus detachment ua rau mob stroke thiab lwm yam embolism. Los ntawm inhibiting platelet activation thiab txo cov thrombus fragment shedding, qhov xwm txheej ntawm cov xwm txheej no tuaj yeem txo tau zoo. Piv txwv li, thaum kho PCI, tso lub catheter los ntawm cov hlab ntsha mus rau hauv lub plawv cov hlab ntsha tuaj yeem ua rau cov hlab ntsha puas. Yog tias tus neeg mob muaj kev pheej hmoo siab ntawm thrombus detachment, tom qab kev siv eptifibatide tuaj yeem txo qhov kev pheej hmoo ntawm mob stroke los ntawm thrombus detachment thiab muab kev txhawb zog rau tus neeg mob lub sij hawm ntev - prognosis.
Raws li luv luv -lub sij hawm bridging kho tom qab thrombolysis thiab cov txheej txheem cuam tshuam
Rau cov neeg mob uas muaj tus mob ST ntu nce siab myocardial infarction, yog tias tsis tuaj yeem cuam tshuam kev phais mob raws sij hawm lossis muaj contraindications rau thrombolysis, kev txhaj tshuaj ntawm eptifibatide tuaj yeem muab tso ua ntej txhawm rau txhim kho tus mob, thiab kev cuam tshuam kev kho mob tuaj yeem ua tiav tom qab muaj kev tso cai. Tsis tas li ntawd, rau cov neeg mob uas tsis muaj lub cev tsis muaj zog ntawm cov hlab ntsha ntawm cov hlab ntsha ntawm cov hlab ntsha bypass grafting, kev sib xyaw ua ke ntawm eptipatide thiab sodium unfractionated heparin thaum lub sijhawm ua haujlwm tuaj yeem ua rau muaj kev sib koom ua ke los tiv thaiv coagulant, txo qhov kev phais thiab lub sijhawm hemostasis, thiab txhim kho qhov ua tiav thiab kev nyab xeeb ntawm kev phais.
Qhov chaw:39Drug Tong, Minfukang, Baidu Baike
Kev tiv thaiv kab mob thrombotic
Thrombosis yog ib hom kab mob pathological rau ntau yam kab mob plawv thiab cerebrovascular, thiabKev txhaj tshuaj eptifibatideplays lub luag haujlwm tseem ceeb hauv kev tiv thaiv kab mob thrombotic los ntawm inhibiting platelet aggregation
Tiv thaiv cov hlab ntsha stenosis lossis txhaws
Nws tuaj yeem txhim kho cov atheromatous plaque, tiv thaiv nws cov rupture los ntawm kev ua rau thrombosis, thiab tom qab ntawd tiv thaiv qhov tshwm sim ntawm coronary stenosis los yog txhaws. Rau cov neeg mob uas muaj kab mob plawv thiab paj hlwb yav dhau los, ua raws li tus kws kho mob cov lus qhia kom noj eptibatide rau kev kho antiplatelet sib sau ua ke tuaj yeem txo qhov kev pheej hmoo ntawm cov kab mob thrombotic. Piv txwv li, tus neeg mob uas tau raug kev txom nyem los ntawm myocardial infarction thiab txuas ntxiv siv nws thaum lub sij hawm kho kom rov zoo tuaj yeem txo qhov muaj peev xwm ntawm cov hlab ntsha coronary thrombosis rov tsim thiab tiv thaiv lub plawv ua haujlwm.
Tiv thaiv kom tsis txhob muaj cov hlab ntsha ntxiv
Tom qab kev phais mob plawv, yog tias thrombosis tshwm sim, nws tuaj yeem siv tau raws li kev qhia ntawm tus kws kho mob txhawm rau tiv thaiv cov hlab ntsha ntxiv. Piv txwv li, rau cov neeg mob uas tsis muaj contraindications xws li los ntshav, nruam intravenous infusion ntawm eptifibatide tom qab percutaneous coronary kev cuam tshuam yuav inhibit platelet aggregation ntawm lub stent nto, tiv thaiv vascular restenosis, thiab tswj vascular patency.
Txo qhov kev pheej hmoo ntawm mob stroke
Los ntawm inhibiting platelet aggregation thiab txo qhov distal embolism tshwm sim los ntawm thrombus shedding, txoj kev pheej hmoo ntawm mob stroke tuaj yeem txo qis. Nws yog qhov tshwj xeeb tshaj yog tsim rau cov neeg muaj kev pheej hmoo siab xws li lub plawv dhia siab, hnub nyoog laus, yav dhau los myocardial infarction, cerebral ischemia ib ntus lossis mob stroke, thiab keeb kwm ntshav qab zib. Cov pej xeem no muaj feem ntau dua ntawm kev tsim mob stroke vim muaj ntau yam kev pheej hmoo, thiab lawv daim ntawv thov muab kev tiv thaiv zoo rau lawv.
Qhov chaw:39Drug Tong, Minfukang, Baidu Baike
Kev txhim kho vascular kev ua haujlwm
Etriptide muaj ntau lub tswv yim ntawm kev ua haujlwm hauv kev txhim kho vascular muaj nuj nqi, muab kev tiv thaiv kev tiv thaiv kab mob plawv:
nthuav cov hlab ntsha
Nws tuaj yeem ua rau cov leeg nqaij leeg ntawm cov hlab ntsha, ua rau lawv so, yog li ua kom cov ntshav myocardial txaus thiab txhim kho cov ntshav tsis txaus rau lub plawv. Cov nyhuv no pab txo cov tsos mob angina thiab txhim kho lub neej zoo rau cov neeg mob. Piv txwv li, thaum tus neeg mob ntsib myocardial ischemia vim mob hlab ntsha tawg, dilation tuaj yeem txo qhov spasm sai, kho cov ntshav mus rau myocardium, thiab txo cov tsos mob xws li mob hauv siab.
Txhawb kev kho endothelial cell
Cov hlwb endothelial ua lub luag haujlwm tseem ceeb hauv kev tswj hwm vascular kev ua haujlwm. Nws tuaj yeem ua rau cov hlwb puas endothelial tso tawm cov txiaj ntsig kev loj hlob, ua kom cov kab mob endothelial cell migration thiab proliferation, pab kho cov phab ntsa vascular puas, thiab rov ua haujlwm vascular. Piv txwv li, nws tuaj yeem tsim cov hlwb endothelial los tsim nitric oxide (NO), uas yog ib qho tseem ceeb ntawm kev so ntawm endothelial uas tuaj yeem cuam tshuam rau cov leeg nqaij leeg, ua rau vasodilation, thaum tseem inhibiting platelet aggregation thiab adhesion, txo txoj kev pheej hmoo ntawm thrombosis.
Regulating proliferation thiab migration ntawm vascular smooth leeg hlwb
Qhov txawv txav ntawm kev loj hlob thiab kev tsiv teb tsaws ntawm vascular du leeg hlwb yog qhov tseem ceeb ua rau cov phab ntsa vascular thickening thiab nqaim ntawm lumen. Los ntawm kev tswj cov kev loj hlob thiab kev tsiv teb tsaws ntawm vascular du leeg hlwb, kev ua haujlwm ntawm cov phab ntsa vascular tau txhim kho, thiab cov phab ntsa vascular smoothness thiab cov ntshav ntws tau zoo. Piv txwv li, thaum lub sij hawm kev loj hlob ntawm atherosclerosis, vascular du leeg hlwb yuav tsiv los ntawm nruab nrab daim nyias nyias mus rau intima thiab proliferate, tsim atherosclerotic plaques. Etibatide tuaj yeem cuam tshuam cov txheej txheem no thiab txo qis kev loj hlob ntawm atherosclerosis.
Qhov chaw:39Drug Tong, Baidu Baike
Kev ncua ntev ntawm atherosclerosis
Atherosclerosis yog lub hauv paus pathological ntawm kab mob plawv thiab mob hlab ntsha tawg, thiab nws txoj kev vam meej yog ze ze rau qib qis lipoprotein cholesterol (LDL - C). LDL - qib C tuaj yeem txo los ntawm ntau txoj hauv kev, yog li ua kom qeeb lossis tiv thaiv kev loj hlob ntawm atherosclerosis:
Inhibit LDL -C oxidation
Oxidative LDL - C yog ib qho tseem ceeb hauv kev tsim cov atherosclerosis. Txo qhov tsim ntawm lub hlwb ua npuas ncauj los ntawm inhibiting qhov uptake ntawm oxidized LDL - C. Ua npuas ncauj hlwb yog cov khoom tseem ceeb ntawm atherosclerotic plaque, thiab txo nws cov tsim yuav ua tau zoo ncua kev loj hlob ntawm atherosclerotic plaque.
Regulating lipid metabolism
Eptifibatide txhaj tshuajtuaj yeem cuam tshuam rau kev ua haujlwm ntawm lipid metabolism ntsig txog cov enzymes thiab txhawb cov synthesis ntawm siab -cov roj lipoprotein ceev (HDL-C). HDL - C muaj kev ua haujlwm ntawm kev tiv thaiv atherosclerosis. Nws tuaj yeem thauj cov roj cholesterol hauv cov ntaub so ntswg mus rau lub siab rau cov metabolism, yog li txo qis cov roj cholesterol hauv cov ntshav. Etriptide ntxiv txhim kho cov hlab plawv kev noj qab haus huv los ntawm kev tswj cov lipid metabolism tsis zoo.
Qhov chaw:39 Drug Tong
FAQ
Puas yog eptifibatide yog anticoagulant?
Nws yog ib qho tshuaj tiv thaiv -coagulant uas xaiv thiab thim rov qab thaiv cov platelet glycoprotein IIb/IIIa receptor.
Dab tsi yog eptifibatide siv rau?
Integrilin: Package Insert / Prescribing Information / MOAeptifibatide yog cov tshuaj platelet inhibitor (glycoprotein IIb / IIIa inhibitor) siv rau kev kho mob plawv thaum muaj xwm txheej ceev los tiv thaiv cov ntshav txhaws, plawv nres, lossis tuag. Nws yog feem ntau muab tso rau hauv cov neeg mob uas muaj mob coronary syndrome (ACS), suav nrog cov neeg uas tsis ruaj tsis khov angina, NSTEMI, lossis cov uas tau txais kev cuam tshuam rau percutaneous coronary intervention (PCI) nrog stenting.
Cim npe nrov: Tuam Tshoj eptifibatide txhaj tshuaj manufacturers, lwm tus neeg
